| Description | TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/8/9 antagonist 2 can be used to study auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis. |
| In vitro | TLR7/8/9 antagonist 2 exhibited inhibitory activity against HEK/hTLR7, HEK/hTLR8, and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM, and 0,052 μM, respectively.[1]TLR7/8/9 antagonist 2 showed inhibitory activity against hPBMC/TLR9 with an IC50 value of 420 nM.[1] |
| In vivo | TLR7/8/9 antagonist 2 has a high in vivo bioavailability.[1] |
| Target activity | HEK/hTLR7:0.011 μM, HEK/hTLR8:0.029 μM, HEK/hTLR9:0.052 μM |
| molecular weight | 405.54 |
| Molecular formula | C23H31N7 |
| CAS | 2920729-91-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Dongdong Chen, et al. Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease. Patent WO2023046806A1. |